Cargando…

Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy

BACKGROUND: Circulating microRNAs may represent novel markers for cardiovascular diseases. We evaluated whether circulating miRNAs served as potential biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy (HCM). METHODS: Cardiac magnetic resonance imaging with postc...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Lu, Ellims, Andris H., Moore, Xiao-lei, White, David A., Taylor, Andrew J., Chin-Dusting, Jaye, Dart, Anthony M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581079/
https://www.ncbi.nlm.nih.gov/pubmed/26404540
http://dx.doi.org/10.1186/s12967-015-0672-0
_version_ 1782391491819208704
author Fang, Lu
Ellims, Andris H.
Moore, Xiao-lei
White, David A.
Taylor, Andrew J.
Chin-Dusting, Jaye
Dart, Anthony M.
author_facet Fang, Lu
Ellims, Andris H.
Moore, Xiao-lei
White, David A.
Taylor, Andrew J.
Chin-Dusting, Jaye
Dart, Anthony M.
author_sort Fang, Lu
collection PubMed
description BACKGROUND: Circulating microRNAs may represent novel markers for cardiovascular diseases. We evaluated whether circulating miRNAs served as potential biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy (HCM). METHODS: Cardiac magnetic resonance imaging with postcontrast T(1) mapping was performed to non-invasively quantify diffuse myocardial fibrosis in HCM patients who were classified into two groups (T(1) < 470 ms or T(1) ≥ 470 ms, as likely or unlikely to have diffuse fibrosis, respectively). First, we screened 84 miRNAs using human serum/plasma miRNA array on plasma of 8 HCM patients (4/group based on T(1) time) and 4 healthy controls. From the results of this initial array, 16 miRNAs were selected based on their fold changes and relevance to myocardial fibrosis for further validation by Taqman real-time PCR in 55 HCM patients. RESULTS: Among the 16 miRNAs, the expression of miR-96-5p and miR-373-3p was low. The remaining 14 (miR-18a-5p, miR-146a-5p, miR-30d-5p, miR-17-5p, miR-200a-3p, miR-19b-3p, miR-21-5p, miR-193-5p, miR-10b-5p, miR-15a-5p, miR-192-5p, miR-296-5p, miR-29a-3p, and miR-133a-3p) were upregulated in HCM patients with T(1) < 470 ms compared with those with T(1) ≥ 470 ms, and 11 (except miR-192-5p, miR-296-5p and miR-133a-3p) were significantly inversely correlated with postcontrast T(1) values. Individual miRNA had moderate diagnostic value for diffuse myocardial fibrosis (AUC: 0.663–0.742), but the diagnostic value was greatly improved (AUC: 0.87) for a combination of 8 miRNAs. In comparison, circulating markers of collagen turnover did not have predictive values for diffuse myocardial fibrosis. CONCLUSIONS: These findings suggest that circulating miRNAs provide attractive candidates as putative biomarkers for diffuse myocardial fibrosis in HCM. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-015-0672-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4581079
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45810792015-09-25 Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy Fang, Lu Ellims, Andris H. Moore, Xiao-lei White, David A. Taylor, Andrew J. Chin-Dusting, Jaye Dart, Anthony M. J Transl Med Research BACKGROUND: Circulating microRNAs may represent novel markers for cardiovascular diseases. We evaluated whether circulating miRNAs served as potential biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy (HCM). METHODS: Cardiac magnetic resonance imaging with postcontrast T(1) mapping was performed to non-invasively quantify diffuse myocardial fibrosis in HCM patients who were classified into two groups (T(1) < 470 ms or T(1) ≥ 470 ms, as likely or unlikely to have diffuse fibrosis, respectively). First, we screened 84 miRNAs using human serum/plasma miRNA array on plasma of 8 HCM patients (4/group based on T(1) time) and 4 healthy controls. From the results of this initial array, 16 miRNAs were selected based on their fold changes and relevance to myocardial fibrosis for further validation by Taqman real-time PCR in 55 HCM patients. RESULTS: Among the 16 miRNAs, the expression of miR-96-5p and miR-373-3p was low. The remaining 14 (miR-18a-5p, miR-146a-5p, miR-30d-5p, miR-17-5p, miR-200a-3p, miR-19b-3p, miR-21-5p, miR-193-5p, miR-10b-5p, miR-15a-5p, miR-192-5p, miR-296-5p, miR-29a-3p, and miR-133a-3p) were upregulated in HCM patients with T(1) < 470 ms compared with those with T(1) ≥ 470 ms, and 11 (except miR-192-5p, miR-296-5p and miR-133a-3p) were significantly inversely correlated with postcontrast T(1) values. Individual miRNA had moderate diagnostic value for diffuse myocardial fibrosis (AUC: 0.663–0.742), but the diagnostic value was greatly improved (AUC: 0.87) for a combination of 8 miRNAs. In comparison, circulating markers of collagen turnover did not have predictive values for diffuse myocardial fibrosis. CONCLUSIONS: These findings suggest that circulating miRNAs provide attractive candidates as putative biomarkers for diffuse myocardial fibrosis in HCM. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-015-0672-0) contains supplementary material, which is available to authorized users. BioMed Central 2015-09-24 /pmc/articles/PMC4581079/ /pubmed/26404540 http://dx.doi.org/10.1186/s12967-015-0672-0 Text en © Fang et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Fang, Lu
Ellims, Andris H.
Moore, Xiao-lei
White, David A.
Taylor, Andrew J.
Chin-Dusting, Jaye
Dart, Anthony M.
Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy
title Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy
title_full Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy
title_fullStr Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy
title_full_unstemmed Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy
title_short Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy
title_sort circulating micrornas as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581079/
https://www.ncbi.nlm.nih.gov/pubmed/26404540
http://dx.doi.org/10.1186/s12967-015-0672-0
work_keys_str_mv AT fanglu circulatingmicrornasasbiomarkersfordiffusemyocardialfibrosisinpatientswithhypertrophiccardiomyopathy
AT ellimsandrish circulatingmicrornasasbiomarkersfordiffusemyocardialfibrosisinpatientswithhypertrophiccardiomyopathy
AT moorexiaolei circulatingmicrornasasbiomarkersfordiffusemyocardialfibrosisinpatientswithhypertrophiccardiomyopathy
AT whitedavida circulatingmicrornasasbiomarkersfordiffusemyocardialfibrosisinpatientswithhypertrophiccardiomyopathy
AT taylorandrewj circulatingmicrornasasbiomarkersfordiffusemyocardialfibrosisinpatientswithhypertrophiccardiomyopathy
AT chindustingjaye circulatingmicrornasasbiomarkersfordiffusemyocardialfibrosisinpatientswithhypertrophiccardiomyopathy
AT dartanthonym circulatingmicrornasasbiomarkersfordiffusemyocardialfibrosisinpatientswithhypertrophiccardiomyopathy